There are 2949 resources available
86MO - Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes
Presenter: Jacob Adashek
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
87MO - Assessing tumour fraction of CSF cfDNA improves diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis (BCLM)
Presenter: Amanda Fitzpatrick
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
LBA10 - Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types
Presenter: Leonie Voorwerk
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
88MO - T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
Presenter: Marcus Schmidt
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1931MO - A HER3/DUSP6 loop determines sensitivity to HER2-targeted therapies in breast cancer
Presenter: Majid Momeny
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1932MO - Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients
Presenter: Marzia Del Re
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1933MO - TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
Presenter: Marta Palafox
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1815MO - Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial
Presenter: Luigi Celio
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1816MO - ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey
Presenter: Teresa Smit
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1817MO - Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC)
Presenter: Pietro Lapidari
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast